Japan’s cost-effectiveness assessment (CEA) panel has approved a revised handling policy for the CEA system for FY2026, with the health…
HOME > BUSINESS
BUSINESS
- Taiho to Commercialize Otsuka US Subsidiary’s 2 Cancer Drugs in North America
June 10, 2019
- Konica Minolta Joins Hands with Univ. of Tokyo, NCC on Genetic Profiling
June 7, 2019
- Royalties Push Up Profits at 3 Major Makers, Shionogi Sees 40% Operating Margin This Year
June 7, 2019
- Boehringer’s Japan Pharma Sales on Course for Recovery; Jardiance, Spiolto Upbeat
June 7, 2019
- Astellas Ties Up with Microsoft to Develop Tool Using “Mixed Reality” to Improve Medication Adherence
June 7, 2019
- Fujifilm Toyama Chemical’s T-817MA Enters PII to Examine Post-Stroke Rehabilitation Enhancement Effects
June 7, 2019
- Takeda Calls Off PIII Study of Sakigake-Designated Ninlaro for AL Amyloidosis after Failing to Hit Primary Goal
June 7, 2019
- Merck SVP Roy Baynes Recounts Keytruda Development, Says We Followed Science
June 6, 2019
- Japan Fair Trade Watchdog Issues Cease and Desist and Surcharge Payment Orders to Koa Isei for Price Fixing
June 6, 2019
- Otsuka Chemical Acquires Cefixime-Related Business from Astellas
June 6, 2019
- Fujifilm Develops Continuous Production System for Biologics, Set to Begin Contract Manufacturing in 2020
June 6, 2019
- Fujifilm Invests 200 Million Yen in Cell Therapy Startup
June 5, 2019
- Xofluza Hits Goal of Preventing Flu Onset in Japan PIII: Shionogi
June 5, 2019
- Astellas’s ADC Enfortumab Vedotin Logs 44% ORR in Advanced Urothelial Cancer in PII
June 5, 2019
- Amazon Web Services to Enhance Services for Healthcare Industry in Japan
June 5, 2019
- Takeda’s Takhzyro Reduces HAE Attacks in Initial Phase of Treatment
June 5, 2019
- No Japanese Enrolled, but AstraZeneca to Discuss Lynparza’s Pancreatic Cancer Data with PMDA: Oncology Chief
June 4, 2019
- Alecensa Slashes Progression Risk by 63% vs. Xalkori in Frontline NSCLC
June 4, 2019
- Lumicef Now in Japan PIII for Systemic Sclerosis: Kyowa Kirin
June 4, 2019
- Alecensa Filed in Japan for Rare Lymphoma: Chugai
June 4, 2019
ページ
Chugai Pharmaceutical’s Duchenne muscular dystrophy (DMD) gene therapy Elevidys has finally reached the Japanese market after months of safety reviews…
I recently sat down with one of the leading medical directors in Japan to discuss the critical evolution of the medical science liaison (MSL) role.The MSL has transformed from a scientific resource into a strategic partner essential for successful product…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…